NautaDutilh has assisted clinical-stage genetic medicines company Vico Therapeutics on its EUR 54 million Series B financing round.
The funding will be used for the development of therapies for severe neurological diseases, in particular the Phase 1/2a trial of its lead product candidate VO659 which is being developed for multiple polyglutamine disorders, spinocerebellar ataxia type 3, type 1 and Huntington's disease.
“It has been a great pleasure to support Vico in reaching this important milestone, which will enable them to accelerate their efforts to advance their VO659 clinical-stage program for certain rare devastating neurodegenerative diseases for which there are currently no disease-modifying treatments available.”
The financing was led by new investor Ackermans & van Haaren (AvH) and by existing investors Droia Ventures, EQT Life Sciences and Kurma Partners, with participation of existing investors Polaris Partners, Pureos Bioventures and Eurazeo.